tiprankstipranks
Advertisement
Advertisement

HK:1952 Stock Latest News

Everest Medicines Director and Major Shareholder Raises Stake in Company
Company AnnouncementsEverest Medicines Director and Major Shareholder Raises Stake in Company
6d ago
1952
Everest Medicines Details PSVT Asset Purchase and Readies for China Launch
PremiumCompany Announcements
Everest Medicines Details PSVT Asset Purchase and Readies for China Launch
24d ago
1952
Everest Medicines to Buy Asia-Pacific Chronic Disease Portfolio in US$250 Million Deal
PremiumCompany Announcements
Everest Medicines to Buy Asia-Pacific Chronic Disease Portfolio in US$250 Million Deal
1M ago
1952
Everest Medicines Honorary Chairman Boosts Stake in Company
PremiumCompany Announcements
Everest Medicines Honorary Chairman Boosts Stake in Company
2M ago
1952
Everest Medicines Publishes Audited 2025 Annual Results and Report
PremiumCompany Announcements
Everest Medicines Publishes Audited 2025 Annual Results and Report
2M ago
1952
Everest Medicines to Acquire Cardiovascular Drug Assets in Up to US$50 Million Deal
PremiumCompany AnnouncementsEverest Medicines to Acquire Cardiovascular Drug Assets in Up to US$50 Million Deal
2M ago
1952
Everest Medicines Pays RMB200 Million Deposit for Potential Asia-Pacific Chronic Disease Portfolio Acquisition
Premium
Company Announcements
Everest Medicines Pays RMB200 Million Deposit for Potential Asia-Pacific Chronic Disease Portfolio Acquisition
2M ago
1952
Everest Medicines Sets March 2026 Board Meeting to Approve 2025 Annual Results
Premium
Company Announcements
Everest Medicines Sets March 2026 Board Meeting to Approve 2025 Annual Results
2M ago
1952
Everest Medicines Shareholders Approve Commercial Pact and New 2026 Equity Incentive Scheme
PremiumCompany Announcements
Everest Medicines Shareholders Approve Commercial Pact and New 2026 Equity Incentive Scheme
3M ago
1952
Everest Medicines Wins China Approval for Ulcerative Colitis Drug VELSIPITY and Outlines Ambitious 2030 Growth Plan
PremiumCompany Announcements
Everest Medicines Wins China Approval for Ulcerative Colitis Drug VELSIPITY and Outlines Ambitious 2030 Growth Plan
3M ago
1952
Everest Medicines Secures Exclusive Asian Rights to First-in-Class SHPT Drug MT1013
PremiumCompany Announcements
Everest Medicines Secures Exclusive Asian Rights to First-in-Class SHPT Drug MT1013
4M ago
1952
Everest Medicines Calls Virtual EGM to Approve Commercial Deal and New Share Incentive Plan
PremiumCompany Announcements
Everest Medicines Calls Virtual EGM to Approve Commercial Deal and New Share Incentive Plan
4M ago
1952
Everest Medicines Sets February 2026 Date and Book Closure for Extraordinary General Meeting
PremiumCompany AnnouncementsEverest Medicines Sets February 2026 Date and Book Closure for Extraordinary General Meeting
4M ago
1952
Everest Medicines Signs Connected Lease for Expanded Shanghai R&D and Production Site
Premium
Company Announcements
Everest Medicines Signs Connected Lease for Expanded Shanghai R&D and Production Site
4M ago
1952
Everest Medicines Delays Shareholder Circular on Commercialization Service Agreement
Premium
Company Announcements
Everest Medicines Delays Shareholder Circular on Commercialization Service Agreement
4M ago
1952
Everest Medicines Chairman Boosts Stake With HK$1.14 Million Share Purchase
PremiumCompany Announcements
Everest Medicines Chairman Boosts Stake With HK$1.14 Million Share Purchase
5M ago
1952
Everest Medicines Warns on NEFECON Patent as Generic Wins China Approval
PremiumCompany Announcements
Everest Medicines Warns on NEFECON Patent as Generic Wins China Approval
5M ago
1952
Everest Medicines Directors and Major Shareholder Increase Stake, Signaling Confidence
PremiumCompany Announcements
Everest Medicines Directors and Major Shareholder Increase Stake, Signaling Confidence
5M ago
1952
Everest Medicines Announces Strategic Commercialization Agreement in China
PremiumCompany Announcements
Everest Medicines Announces Strategic Commercialization Agreement in China
5M ago
1952
Everest Medicines Announces Board Composition and Committee Roles
PremiumCompany AnnouncementsEverest Medicines Announces Board Composition and Committee Roles
5M ago
1952
Everest Medicines Expands into Ophthalmology with VIS-101 Agreement
Premium
Company Announcements
Everest Medicines Expands into Ophthalmology with VIS-101 Agreement
7M ago
1952
Everest Medicines Grants Options to Chairman to Enhance Governance
Premium
Company Announcements
Everest Medicines Grants Options to Chairman to Enhance Governance
7M ago
1952

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >